- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharma Pulse 11/7/24: Women Within Health Care Face Financial Disparities, The New Frontier for Clinical Research Excellence & more
The latest news for pharma industry insiders.
Site QMS-Based Site Monitoring: The New Frontier for Clinical Research Excellence
Moving towards the development of mature quality management systems.
Women Within Health Care Face Financial Disparities and Are More Likely to Experience Burnout
The authors believe that improvements can be made to overlook the motherhood penalty and its associated pay gaps as well as changes to address workforce burnout.
Election Wargames: Tech and Politics Try Their Hands at Detecting Voting Threats
‘Risk games’ hosted by Lux Capital expose the difficulty of identifying technology-related election threats.
The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com offering.
The rapid evolution of antibody drug conjugates reflects their clinical and commercial success, with 16 products currently approved across various markets and sales surpassing US$ 10 Billion in 2023 and US$ 7 Billion in the first 6 months of 2024. This growth highlights antibody drug conjugates as a commercially viable segment of the broader cancer therapeutics market, prompting increased research and development efforts to create more effective and safer candidates.
How are pharma supply chains adapting to new regulations and industry trends? Kenco’s VP of Life Sciences, Tim McClatchy, outlines three key challenges in Pharmaceutical Commerce Magazine. Dive into the details here!
#lifesciences #PharmaceuticalCommerce #supplychain #3pl #Kenco
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
